IBO revenueQ2 2026$3.0K
- Quarter YoY
- -57.1%
- QoQ
- -57.1%
IBO revenue was $3.0K in fiscal Q2 2026 (ended Jun 30, 2026), down 57.1% from a year earlier and down 57.1% from the prior quarter. For the full fiscal 2025 it was $32.0K.
Impact BioMedical Inc. (IBO) financials
For the twelve months ended Jun 30, 2026, Impact BioMedical Inc. reported $35.0K of revenue and $789.0K of net income.
- Revenue, TTM
- $35.0K
- Net income, TTM
- $789.0K
- Net margin
- 2254.3%
- Cash
- $10.0K
- P/E
- 44.40
- P/S
- 1000.83
- Market cap
- $35.0M
FY2022FY2025
FY2022FY2025
IBO revenue and earnings growth
IBO net incomeQ2 2026-$699.0K
IBO net income was -$699.0K in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$14.35M a year earlier. For the full fiscal 2025 it was -$11.84M, compared with -$24.71M in fiscal 2024.
IBO EPSQ2 2026-$0.01
IBO diluted EPS was -$0.01 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$0.38.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Revenue | $32.0K | - | - | $50.0K |
| Cost of revenue | $424.0K | - | - | - |
| Gross profit | -$392.0K | - | - | - |
| Research and development | $340.0K | $278.0K | $1.69M | $1.23M |
| Selling, general and admin | $873.0K | $718.0K | $315.0K | $325.0K |
| Operating income | -$4.28M | -$28.75M | -$4.03M | -$3.40M |
| Interest expense | $793.0K | $1.06M | $444.0K | $462.0K |
| Pre-tax income | -$14.45M | -$24.74M | -$4.41M | -$7.88M |
| Income tax | -$2.58M | $33.0K | - | -$621.0K |
| Net income | -$11.84M | -$24.71M | -$4.34M | -$7.25M |
| EPS, basic | -$0.38 | -$2.30 | -$0.07 | -$0.10 |
| EPS, diluted | -$0.38 | -$2.30 | -$0.07 | -$0.10 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Cash and equivalents | $3.0K | $2.00M | $1.0K | $2.0K |
| Receivables | $5.0K | $201.0K | $0 | - |
| Inventory | $63.0K | - | - | - |
| Current assets | $411.0K | $2.45M | $332.0K | $122.0K |
| Goodwill | - | $25.09M | $25.09M | $25.09M |
| Total assets | $17.41M | $20.29M | $44.63M | $46.50M |
| Current liabilities | $1.16M | $9.79M | $13.14M | $10.59M |
| Total debt | - | $12.07M | $12.07M | - |
| Total liabilities | $1.85M | $13.05M | $16.37M | $13.83M |
| Shareholders' equity | $12.31M | $7.24M | $28.26M | $32.67M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Operating cash flow | -$1.89M | -$2.85M | -$2.85M | -$2.24M |
| Investing cash flow | $3.0K | $2.0K | -$15.0K | -$349.0K |
| Financing cash flow | -$109.0K | $4.85M | $2.87M | $2.55M |
| Stock-based compensation | $13.0K | $19.0K | - | - |
| Depreciation and amortization | $1.15M | $1.12M | $1.12M | $1.11M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Gross margin | -1225.0% | - | - | - |
| Operating margin | -13381.3% | - | - | -6808.0% |
| Net margin | -36993.8% | - | - | -14510.0% |
| Return on equity | -96.2% | -341.4% | -15.3% | -22.2% |
| Return on assets | -68.0% | -121.8% | -9.7% | -15.6% |
| Current ratio | 0.35 | 0.25 | 0.03 | 0.01 |
| Debt to equity | - | 1.67 | 0.43 | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0K | $7.0K | $7.0K | $18.0K | $7.0K | $0 | - | - | - | - | - | - |
| Cost of revenue | $1.0K | $0 | $422.0K | $1.0K | $1.0K | $0 | - | - | - | - | - | - |
| Gross profit | $2.0K | $7.0K | -$415.0K | $17.0K | $6.0K | $0 | - | - | - | - | - | - |
| Research and development | $76.0K | $46.0K | $110.0K | $52.0K | $75.0K | $103.0K | -$108.0K | $82.0K | $121.0K | $183.0K | $630.0K | $357.0K |
| Selling, general and admin | $167.0K | $1.62M | $118.0K | $261.0K | $246.0K | $248.0K | $294.0K | $132.0K | $145.0K | $148.0K | $133.0K | $101.0K |
| Operating income | -$702.0K | -$2.29M | -$1.17M | -$948.0K | -$1.15M | -$1.01M | -$26.23M | -$1.13M | -$626.0K | -$771.0K | -$1.14M | -$1.08M |
| Interest expense | - | - | $0 | $262.0K | $260.0K | $271.0K | $270.0K | $305.0K | $261.0K | $230.0K | $125.0K | $102.0K |
| Pre-tax income | -$700.0K | -$2.28M | $2.65M | -$1.48M | -$14.35M | -$1.28M | -$27.10M | $4.24M | -$884.0K | -$998.0K | -$1.26M | -$1.18M |
| Net income | -$699.0K | -$2.29M | $5.25M | -$1.47M | -$14.35M | -$1.27M | -$27.11M | $4.25M | -$889.0K | -$962.0K | -$1.19M | -$1.16M |
| EPS, basic | -$0.01 | -$0.02 | - | -$0.12 | -$1.18 | -$0.11 | - | $0.37 | -$0.09 | -$0.10 | - | -$0.02 |
| EPS, diluted | -$0.01 | -$0.02 | - | -$0.12 | -$1.18 | -$0.11 | - | $0.06 | -$0.09 | -$0.10 | - | -$0.02 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $10.0K | $20.0K | $3.0K | $12.0K | $624.0K | $1.32M | $2.00M | $2.67M | $2.0K | $2.0K | $1.0K | $201.0K |
| Receivables | - | - | $5.0K | $15.0K | $200.0K | $4.0K | $201.0K | - | $128.0K | $128.0K | $0 | - |
| Inventory | $62.0K | $63.0K | $63.0K | $485.0K | $486.0K | $489.0K | - | - | - | - | - | - |
| Current assets | $320.0K | $377.0K | $411.0K | $917.0K | $1.48M | $2.18M | $2.45M | $3.17M | $307.0K | $335.0K | $332.0K | $501.0K |
| Goodwill | - | - | - | - | - | - | $25.09M | $25.09M | $25.09M | $25.09M | $25.09M | $46.40M |
| Total assets | $16.75M | $17.09M | $17.41M | $18.21M | $19.06M | $20.05M | $20.29M | $46.70M | $44.12M | $44.36M | $44.63M | $45.08M |
| Current liabilities | $2.04M | $1.69M | $1.16M | $23.79M | $23.17M | $9.97M | $9.79M | $1.14M | $14.50M | $13.86M | $13.14M | $12.27M |
| Short-term debt | - | - | - | - | - | - | - | - | - | - | - | $11.90M |
| Total debt | - | - | - | - | - | - | $12.07M | - | - | - | $12.07M | - |
| Total liabilities | $2.73M | $2.38M | $1.85M | $27.06M | $26.44M | $13.24M | $13.05M | $12.34M | $17.73M | $17.09M | $16.37M | $15.50M |
| Shareholders' equity | $10.77M | $11.46M | $12.31M | -$11.81M | -$7.38M | $6.81M | $7.24M | $34.35M | $26.38M | $27.26M | $28.26M | $29.58M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $470.0K | -$464.0K | $99.0K | -$613.0K | -$694.0K | -$682.0K | -$986.0K | -$1.00M | -$385.0K | -$482.0K | -$433.0K | -$671.0K |
| Investing cash flow | $2.0K | -$1.0K | $1.0K | $1.0K | $0 | $1.0K | $0 | $1.0K | - | - | $1.0K | -$1.0K |
| Financing cash flow | - | $482.0K | - | - | - | - | $317.0K | $3.67M | $384.0K | $483.0K | $232.0K | $870.0K |
| Stock-based compensation | $0 | $1.44M | $8.0K | $1.0K | $2.0K | $2.0K | - | - | - | - | - | - |
| Depreciation and amortization | $284.0K | $285.0K | $286.0K | $288.0K | $288.0K | $283.0K | $279.0K | $281.0K | $279.0K | $280.0K | $280.0K | $280.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -57.1% | - | - | - | - | - | - | - | - | - | - | - |
| Gross margin | 66.7% | 100.0% | -5928.6% | 94.4% | 85.7% | - | - | - | - | - | - | - |
| Operating margin | -23400.0% | -32700.0% | -16714.3% | -5266.7% | -16471.4% | - | - | - | - | - | - | - |
| Net margin | -23300.0% | -32671.4% | 74928.6% | -8166.7% | -204942.9% | - | - | - | - | - | - | - |
| Current ratio | 0.16 | 0.22 | 0.35 | 0.04 | 0.06 | 0.22 | 0.25 | 2.79 | 0.02 | 0.02 | 0.03 | 0.04 |
| Debt to equity | - | - | - | - | - | - | 1.67 | - | - | - | 0.43 | - |
Source: XBRL data Impact BioMedical Inc. files with the SEC, latest filing dated Aug 7, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
IBO peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| IBO | $35.0K | - | $789.0K | 2254.3% | $35.0M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $665.19B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $521.00B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $370.96B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $314.81B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $199.88B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $186.77B |
IBO FAQ
6 questionsWhat is IBO revenue?
Impact BioMedical Inc. (IBO) reported $35.0K of revenue for the twelve months ended Jun 30, 2026. Revenue for fiscal 2025 was $32.0K.Is IBO profitable?
Yes. Impact BioMedical Inc. earned $789.0K in net income for the twelve months ended Jun 30, 2026, a net margin of 2254.3%.How much cash and debt does IBO have?
Impact BioMedical Inc. reported $10.0K in cash and cash equivalents on its most recent balance sheet in SEC filings.What is IBO gross margin?
Impact BioMedical Inc.'s gross profit was -$389.0K on $35.0K of revenue for the twelve months ended Jun 30, 2026, a gross margin of -1111.4%.When did IBO last report financial results?
The latest statements here come from Impact BioMedical Inc.'s 10-Q filed on Aug 7, 2026, covering the period ended Jun 30, 2026.Where does this IBO financial data come from?
Quantisnow builds these statements from the structured XBRL data Impact BioMedical Inc. files with the SEC. It is provided for information only and is not investment advice.